Compare EBS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBS | CABA |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 339.1M |
| IPO Year | 2006 | 2019 |
| Metric | EBS | CABA |
|---|---|---|
| Price | $5.10 | $0.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $10.00 | ★ $11.75 |
| AVG Volume (30 Days) | 946.0K | ★ 4.3M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.83 | 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $742,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.36 | $0.98 |
| 52 Week High | $14.06 | $4.23 |
| Indicator | EBS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 26.50 |
| Support Level | $4.36 | N/A |
| Resistance Level | $7.18 | $1.59 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 3.79 | 0.76 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.